Arvanitis Constadina, Felsher Dean W
Departments of Medicine and Pathology, Division of Oncology, School of Medicine, Stanford University, CCSR 1105B, 269 Campus Drive, Stanford, CA 94305-5151, USA.
Cancer Lett. 2005 Aug 26;226(2):95-9. doi: 10.1016/j.canlet.2004.10.043. Epub 2004 Dec 16.
MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.
MYC是最早被确定与染色体畸变相关的癌基因之一，也是参与癌症发病机制最常见的癌基因之一。然而，直到最近，MYC是否会成为癌症治疗的一个良好靶点仍不明确。新的条件性转基因模型已被用于证明，即使是MYC的短暂失活也能逆转肿瘤发生。在此，我们综述了近期实验模型系统的结果，这些结果表明，MYC的失活可能是对多种癌症的一种特异性且有效的治疗方法。
